BB Biotech AG

DGAP-Adhoc: BB Biotech AG with loss in the business year 2016

DGAP-Ad-hoc: BB BIOTECH AG / Key word(s): Profit Warning
BB Biotech AG with loss in the business year 2016

13-Jan-2017 / 18:10 CET/CEST
Disclosure of an inside information acc. to Article 17 MAR, transmitted by DGAP
- a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

Media Release, January 13, 2017

BB Biotech AG with loss in the business year 2016

In accordance with regulations on ad hoc publicity, BB Biotech AG (ISIN
CH0038389992) is releasing the following information about its results for the
business year 2016.

After a very volatile year of the biotechnology stock market BB Biotech AG
closed the business year 2016 based on preliminary unaudited consolidated
results with a loss of approximately CHF 802 million (CHF 653 million profit in
the previous year).

BB Biotech's share price increased 0.3% in CHF and 1.9% in EUR during the
business year 2016.

As an investment company, the results reflect the performance of the stocks it
holds in its investment portfolio.

The publication of the Portfolio will take place on January 20, 2017 and the
complete Annual Report will be published on February 17, 2017.

For further information:
Bellevue Asset Management AG, Seestrasse 16, 8700 Küsnacht, Switzerland Tanja
Chicherio, Tel. +41 44 267 67 07,

Company profile

BB Biotech invests in companies in the fast growing market of biotechnology and
is one of the world's largest investors in this sector. BB Biotech is listed in
Switzerland, Germany and Italy. Its investments are focused on listed companies
that are developing and commercializing novel medical treatments and cures. BB
Biotech's investment selection process is guided by the fundamental research and
analysis of physicians and molecular biologists. Its Board of Directors has many
years of experience in industry and science.
13-Jan-2017 CET/CEST The DGAP Distribution Services include Regulatory
Announcements, Financial/Corporate News and Press Releases.
Archive at

Language: English


          Schwertstrasse 6

          8200 Schaffhausen


Phone:    +41 52 624 08 45

Fax:      +41 1 267 67 01


ISIN:     CH0038389992

WKN:      A0NFN3

Listed:   Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial
Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart; SIX


End of Announcement DGAP News Service


536365  13-Jan-2017 CET/CEST

Weitere Meldungen: BB Biotech AG

Das könnte Sie auch interessieren: